TD Cowen raised the firm’s price target on Avidity Biosciences (RNA) to $78 from $56 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 earnings preview.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity announces FDA removed partial clinical hold on Delpacibart Etedesiran
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 9/24/2024, According to Top Analysts
- Avidity Biosciences initiated with a Buy at Goldman Sachs
- 3 Best Stocks to Buy Now, 8/29/2024, According to Top Analysts